Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: mucoadhesive oral wound rinse, laboratory biomarker analysis; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Eribulin, Adriamycin, Cyclophosphamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Breast Cancer
Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 57
States / cities: Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more

Conditions: Osteoporosis, Osteopenia
Interventions: Alendronate, Calcium Citrate, Vitamin D; Drug · Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 59 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Birmingham, Alabama • Jasper, Alabama • Mesa, Arizona + 26 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet transplantation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight and Obesity, Physical Activity, Incentives
Interventions: self-monitoring, daily incentives, delayed lump sum incentives; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Breast Cancer Survivors
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions: Mammaglobin-A DNA Vaccine, Optional biopsy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: chemotherapy, endocrine therapy, DNA methylation analysis, protein analysis, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, conventional surgery, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast, Breast Cancer, Osteoporosis
Interventions: High Dose Vitamin D, Standard of Care Vitamin D; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Breast Cancer, Adherence, Medication, Side Effect
Interventions: BETA-Text text messaging intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gestational Diabetes, Hyperglycemia
Interventions: Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c; Device · Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Neoplasms
Interventions: Dietary/Physical Activity intervention, Usual Care; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: COVID-19, SARS-CoV 2
Interventions: Bicalutamide 150 Mg Oral Tablet; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: compliance monitoring, medical chart review, questionnaire administration; Behavioral · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
Interventions: Abemaciclib, Fulvestrant, Aromatase Inhibitors; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Carcinoma, Pancreatic Ductal
Interventions: Napabucasin, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 99
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 89 more

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Cystic Fibrosis Related Diabetes
Interventions: Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover; Device · Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 32 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions: Metformin XR, Saxagliptin, Saxagliptin-Metformin XR; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 47
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more

Conditions: Chronic Pain, Pain, Chronic, Pain Syndrome, Pain, Neuropathic, Pain, Intractable
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Texture Analysis for Postmenopausal Osteoporosis

Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

Islet Transplantation for Patients With Type 1 Diabetes

Understanding Mechanisms of Exercise Behavior Change

A Study of Attention and Memory Processes in Breast Cancer Survivors

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation

Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Lifestyle, Exercise, and Nutrition Study Early After Diagnosis

Trial to Promote Recovery From COVID-19 With Endocrine Therapy

Compliance to a Hormone Therapy Regimen in Breast Cancer

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Investigating Biological Targets, Markers, and Intervention for Chronic Pain